Table 1.

Priority categories for radiation oncology for patients with BC during the COVID-19 pandemic per the COVID-19 Pandemic Breast Cancer Consortium [7••]

Priority level	Patient description
A	·Bleeding/painful/symptomatic local, regional or metastatic disease ·Progression of disease during neoadjuvant chemotherapy
B1	·Inflammatory BC after mastectomy ·LN + TNBC or HER2 + disease following mastectomy ·4 or more positive lymph nodes ·Residual and LN + disease following neoadjuvant chemotherapy
B2	·1–3 positive lymph nodes following mastectomy ·TNBC or HER2 + , LN- s/p BCS ·Positive margin for invasive cancer s/p BCS with no alternative option (TNBC takes priority)
B3	·Positive margin s/p BCS for invasive cancer with alternative therapy options ·Young age (≤ 40 yrs) s/p BCS, LN- with ≥ 1 high feature (LVI + , PNI +) ·ER- DCIS with positive margin
C	·All other DCIS · > 65 yrs, early stage, LN-, ER + /HER2- s/p BCS and taking endocrine therapy

BC breast cancer, LN lymph node, TNBC triple negative breast cancer, HER2 human epidermal growth factor receptor 2, ER estrogen receptor, DCIS ductal carcinoma in situ